Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Novel PCSK9 Inhibitor Lowers Lipids Across the BoardBlocking PCSK9 synthesis via RNA interference with inclisiran significantly reduces atherogenic lipoproteins in addition to
the results seen with LDL cholesterol, secondary ORION 1 analysis shows.
Medscape Medical News, May 15, 2018
Large Lipoprotein(a) Reductions Needed for Clinical BenefitAbsolute Lp(a) level reductions of 100 mg/dL are needed to substantially reduce coronary heart disease risk, potentially explaining
the relative failure of recent trials, say US researchers.
Medscape Medical News, May 08, 2018
Lp(a) Levels May Modulate CV Benefits of Evolocumab: FOURIERPatients with higher baseline lipoprotein(a) levels have a greater reduction in cardiovascular events with the PSCK9 inhibitor
evolocumab, suggesting potential pleiotropic effects, researchers say.
